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Summary
 
The role of memory T cells during the immune response against random antigenic variants has
not been resolved. Here, we show by simultaneous staining with two tetrameric major histo-
compatibility complex (MHC)–peptide molecules, that the polyclonal CD8
 
1
 
 T cell response
against a series of natural variants of the influenza A nucleoprotein epitope is completely domi-
nated by infrequent cross-reactive T cells that expand from an original memory population.
Based on both biochemical and functional criteria, these cross-reactive cytotoxic T cells pro-
ductively recognize both the parental and the mutant epitope in vitro and in vivo. These results
provide direct evidence that the repertoire of antigen-specific T cells used during an infection
critically depends on prior antigen encounters, and indicate that polyclonal memory T cell
populations can provide protection against a range of antigenic variants.
Key words: inﬂuenza virus • major histocompatibility complex tetramers • peptides •
C57BL mice • in vivo
 
T
 
he small size of the contact surface between the TCR
and MHC-bound peptide suggests that the peptide
specificity in TCR–MHC interactions is limited (1). Indeed,
a large number of studies have demonstrated that the se-
quence requirements for ligand recognition by T cell clones
in vitro are quite minimal (2–5). However, in certain situa-
tions, variations in CTL epitopes may lead to a total or par-
tial loss of functional recognition by cytotoxic T cells, due
to qualitatively different TCR signaling upon interaction
with these altered peptide ligand–MHC complexes (for a
review, see reference 6). Indeed, altered peptide ligands have
been shown to antagonize antigen-specific T cell responses
both in vitro and in vivo (7–14). These experiments have
firmly established that selected mutations in T cell epitopes
can abolish productive T cell recognition. However, it is un-
resolved whether such abortive T cell responses are common
upon in vivo encounter of antigen variants. In an MHC out-
bred population, T cell epitope mutations encountered dur-
ing transient infections are likely to be random, and we
therefore set out to examine how a polyclonal T cell popula-
tion would react to such random antigenic variants in an in
vivo model.
After infection with influenza A viruses, large numbers of
influenza A–specific cytotoxic T cells can be recovered from
pulmonary tissue, lymphoid organs, and peripheral blood in
mice and humans (15–17). In C57BL/10 mice, the immuno-
dominant CTL epitope of influenza A viruses is located in the
viral nucleoprotein (NP),
 
1
 
 amino acids 366–374. Within the
TCR-exposed side chains of the COOH-terminal region of
this peptide (positions 6, 7, and 8), significant variation ex-
ists among naturally occurring influenza A strains. Early work
from Townsend and Skehel (18) showed that certain influ-
enza A virus NP–specific T cell lines can recognize viral vari-
ants in in vitro assays, but the extent and in vivo relevance of
such cross-reactivity have remained elusive. To assess the
consequences of exposure to naturally occurring variants
on T cell reactivity in an in vivo setting, we have analyzed
the effects of polyclonal T cell memory, formed during a
primary influenza A virus infection, on the subsequent re-
sponse against a series of influenza A virus variants. To di-
rectly visualize T cells displaying antigen receptors that are
monospecific for a certain viral variant or that cross-react
between different variants, we used differentially labeled
oligomeric peptide–MHC class I complexes (19). Contrary
to conventional functional assays, such as 
 
51
 
Cr release, this
strategy allows for a direct assessment of the potential for
cross-recognition of individual cells in mixed T cell popu-
lations. The results thus obtained show that cross-reactive
memory T cells generated during a primary infection dom-
inate the T cell response during a secondary infection with
a variant virus even when such cross-reactive cells are rare
 
1
 
Abbreviations used in this paper:
 
 APC, allophycocyanin; HAU, hemagglutinin
unit(s); NP, nucleoprotein; PI, propidium iodide. 
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in the original memory T cell pool. The implications of
these findings for peripheral T cell repertoire selection and
viral variation are discussed.
 
Materials and Methods
 
Animals.
 
C57BL/10 mice at 5–6 wk of age were obtained from
the animal department of the Netherlands Cancer Institute. Mice
were handled at all times in accordance with institutional guidelines.
 
MHC Tetramers and Peptides.
 
Peptides were produced using
standard g-fluorenylmethoxycarbonyl (FMOC) chemistry. Solu-
ble fluorochrome (PE or allophycocyanin [APC])-labeled MHC
tetramers were produced as described previously (17, 19) and
stored frozen in Tris-buffered saline/16% glycerol/0.5% BSA.
 
Viruses and Cells.
 
Influenza A viruses A/NT/60/68 and
A/HKx31 were provided by Dr. R. Gonsalves, National Institute
for Medical Research, London, UK. Influenza virus B/Lee/40
was obtained from the American Type Culture Collection. Mice
were killed at indicated time points after infection, and organs were
removed for further analysis. Inflamed lung tissue and spleens were
minced in single chamber mesh filters. The single cell suspensions
obtained were treated with NH
 
4
 
Cl solution to get rid of contam-
inating erythrocytes, before staining for flow cytometry purposes.
The influenza A virus (A/NT/60/68) NP–derived H-2D
 
b
 
-
restricted CTL epitope, ASNENMDAM, was introduced into EL4
tumor cells by retroviral insertion as a COOH-terminal fusion
with the enhanced green fluorescent protein (eGFP) gene product
(Wolkers, M.C., manuscript in preparation).
 
Flow Cytometry.
 
In all instances, mononuclear cells were
stained with directly labeled mAbs or MHC tetramers. Analysis
was performed on a FACSCalibur™ (Becton Dickinson) using
CELLQuest™ software (Becton Dickinson). Before staining,
propidium iodide (PI) was added to gate for PI-negative (living)
lymphocytes.
 
Cytotoxicity Assay and MHC Monomer Competition Assay.
 
Cyto-
lytic activity of sorted CD8
 
1
 
 T cells derived from inflamed pul-
monary tissue was determined in a standard 5-h 
 
51
 
Cr-release assay.
EL4 target cells were preincubated with peptides for 1 h at 37
 
8
 
C.
Percent specific lysis was calculated from the equation: [(experimen-
tal 
 
51
 
Cr release – spontaneous 
 
51
 
Cr release)/maximal 
 
51
 
Cr release –
spontaneous 
 
51
 
Cr release)] 
 
3 
 
100%.
Spleen-derived mononuclear cells were stained with anti-CD8
mAb in the presence of PE-labeled MHC tetramers containing
increasing concentrations of MHC monomers. Cells were subse-
quently analyzed by flow cytometry.
 
Intracellular IFN-
 
g
 
 Staining.
 
Intracellular cytokine staining was
performed as described (20). In brief, spleen cells were incubated
with peptide (0.5 
 
m
 
M) for 5–6.5 h at 37
 
8
 
C in the presence of re-
combinant human (rh)IL-2 (50 U/ml) and Brefeldin A (0.1 
 
m
 
l/ml).
After incubation, cells were surface stained with anti-CD8a–APC
mAb (PharMingen), incubated in Cytofix/Cytoperm solution
(PharMingen) for 20 min on ice, washed, and stained for intra-
cellular cytokine with anti–IFN-
 
g
 
–FITC (PharMingen) or FITC-
labeled isotype control antibody (PharMingen). Analyses were
performed on a FACSCalibur™ (Becton Dickinson) using CELL-
Quest™ software. Isotype control antibodies resulted only in back-
ground staining (data not shown).
 
Peptide Immunization.
 
Mice were injected subcutaneously with
100 
 
m
 
g peptide in IFA, 4–6 wk after a primary influenza A virus in-
fection. On days 0, 1, and 2, 100 
 
m
 
g anti-CD40 mAb (FGK.45)
was injected intravenously (21). On day 10 after peptide immuni-
zation, spleen cells were used for flow cytometry analysis.
 
Results
 
Selective Expansion of Cross-reactive Influenza A Virus–specific
T Cells.
 
To assess the effect of random antigen variation on
the dynamics of T cell responses in vivo, we infected mice
with pairs of influenza A viruses. These viruses expressed
either the same NP
 
366–374
 
 epitope or epitope variants. The
specificity of the resulting T cell repertoire was assessed by
two-parameter MHC tetramer staining, and association of
MHC tetramers to NK receptors was ruled out through
analysis of CD8b-expressing cells only. When mice are
infected once or twice with either influenza virus strain
A/NT/60/68 or A/PR/8/34, which differ in the sequence
of the immunodominant NP CTL epitope at positions 7
and 8 (ASNENMDAM vs. ASNENMETM), the vast ma-
jority of the resulting NP-specific T cells selectively recog-
nize the epitope of the strain encountered and not that of
the opposite strain (Fig. 1 A, panels 1 and 3). This dominant
role of the peptide side chains at positions 7 and 8 in ligand
recognition by the majority of T cells is in accord with the
prominent contribution of p8 and especially p7 to the
TCR-exposed surface of this peptide–MHC complex (22).
This virus strain specificity of the NP-reactive CTLs
contrasts sharply with the apparent lack of strain specificity
during secondary responses against a variant strain. When
mice that had recovered from a previous infection with in-
fluenza virus strain A/NT/60/68 are challenged with viral
strain A/PR/8/34, most if not all NP
 
PR
 
-reactive T cells are
fully cross-reactive between the two NP variants (Fig. 1 A,
panel 4). This phenomenon is reciprocal: in mice that have
previously experienced infection with strain A/HKx31 (a
reassortant strain with the NP gene from A/PR/8/34), the
NP-reactive T cell population that emerges upon infection
with A/NT/60/68 is fully cross-reactive between the two
viral strains (Fig. 1 A, panel 2).
Although somewhat variable between individual mice,
the extent of binding of the two MHC tetramers appears
independent of the order in which the epitopes were en-
countered over a large series of experiments. To compare
the affinity for primary and secondary antigen in a more di-
rect manner, competition studies were performed. These
experiments demonstrate that the binding of fluorochrome-
labeled MHC tetramers can be inhibited by similar concen-
trations of ASNENMDAM- and ASNENMETM-contain-
ing monomers, indicating equal affinity of the cross-reactive
TCRs for either antigen (Fig. 1 B). In addition, these data rule
out the possibility of dual TCR expression (23, 24) by the
cross-reactive T cells, since both MHC monomers compete
for binding of ASNENMDAM-containing MHC tetramers.
 
Cross-reactivity Correlates with Cross-recognition.
 
The above
results indicate that the subsequent encounter of variants of
a T cell epitope results in the expansion of a cross-reactive
T cell population, as established by biochemical assays. In fact,
this expansion inhibits the expansion of the largely strain-
specific population observed during a regular primary re-
sponse. However, T cell recognition of ligands with similar
affinities can have drastically different functional outcomes,
due to differences in off rates of TCR–ligand interactions 
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reactive T cell population, we examined the kinetics and
composition of this T cell pool. The cross-reactive cyto-
toxic T cell population appears 2–3 d earlier at the site of
infection (i.e., pulmonary tissue; data not shown) than the
antigen-specific T cells during infection of naive mice
(15–17), suggesting that these cells originate from a pre-
existing memory T cell population. Several studies have
shown a narrowing of the antigen-specific polyclonal TCR
repertoire during recall infection, due to the preferential
outgrowth of a subpopulation of memory cells (30–33). In
naive mice that are infected with influenza virus A/PR/8/34,
the repertoire of NP-specific T cells involves a variety of
BV elements (Fig. 3 A). The slight preferential usage of the
BV8.3 element reported previously for C57BL animals in-
fected with influenza virus A/PR8/34 was not observed in
these experiments (34). In contrast, in A/NT/60/68-primed
mice that are infected with influenza virus A/PR/8/34, the
repertoire of A/PR/8/34-specific T cells is highly restricted
(Fig. 3 A). This narrow T cell repertoire is likely to reflect
the affinity maturation observed previously (33) compounded
by the low number of cross-reactive T cells within the
original memory population. In certain animals, the oligo-
clonal nature of the cross-reactive T cell population appears
to be directly visible from double-tetramer analyses of the
influenza-reactive CD8
 
1
 
 T cell population. In these mice,
Figure 1. Selective expansion of cross-reactive T
cells. (A) Naive mice were infected intranasally with
10 hemagglutinin units (HAU) influenza A/NT/
60/68 (H3N2; epitope: ASNENMDAM) or 200
HAU A/HKx31 (H3N2; epitope: ASNENMETM).
4–6 wk after the primary infection, mice were chal-
lenged with 200 HAU influenza A/NT/60/68 (pan-
els 1 and 2) or A/PR/8/34 (panels 3 and 4) (H1N1;
epitope: ASNENMETM). At day 10 after challenge,
mice were killed and lung-infiltrating mononuclear
cells were stained for CD8 and antigen-specific TCR
expression using anti-CD8b mAb and MHC tetra-
mers. Gated CD81 T cells were analyzed for binding
of APC-labeled MHC tetramers with the influenza
A/NT/60/68 epitope and PE-labeled MHC tetra-
mers with the influenza A/PR/8/34 epitope. Iden-
tical results are obtained when challenge is performed with influenza A 81/HO (H7N2; NP366–374 sequence ASNENMDAM) instead of A/NT/60/68, and is
therefore independent of HN subtype (not shown). Results represent the outcome of more than five experiments performed. (B) Mice were sequentially infected
with influenza virus A/HKx31 and A/NT/60/68. On day 7 after the second infection, spleen cells were incubated with MHC tetramers containing the
NP366–374 epitope (ASNENMDAM) of A/NT/60/68. H-2Db monomers complexed with ASNENMDAM (j) or ASNENMETM (m) were added in
increasing amounts, and inhibition of the binding of MHC tetramers to CD81 T cells was determined.
 
(25–29). Therefore, we examined the functional behavior
of this biochemically cross-reactive T cell population towards
both the primary and the mutant epitope. The cross-reac-
tive T cells that are observed during a recall influenza A vi-
rus infection lyse target cells pulsed with both the primary
and the recall antigen directly ex vivo to the same extent
over a wide range of E/T ratios, and over a range of peptide
concentrations (Fig. 2 A).
As an independent test of functional cross-recognition,
we measured the ability of these cells to initiate IFN-
 
g
 
 syn-
thesis upon stimulation with the original or variant epitope.
Since simultaneous staining of cells with MHC tetramers
and intracellular IFN-
 
g
 
 staining is technically difficult, cells
were stimulated in the presence of the original and variant
peptide separately or simultaneously (Fig. 2 B). The pro-
portion of IFN-
 
g
 
–positive CD8
 
1
 
 T cells is similar in all
three cases, indicating that the T cell populations that rec-
ognize the two epitopes are largely overlapping and there-
fore cross-reactive.
We conclude that the T cell population that emerges upon
encounter of an antigenic variant is biochemically cross-reac-
tive, and this cross-reactivity is fully reflected in their func-
tional behavior.
 
Cross-reactive T Cells Are Selectively Expanded Memory T
Cells.
 
To better understand the ontogeny of the cross- 
1322
 
CD8
 
1
 
 Memory T Cell Responses against Viral Variants
 
the expanded cross-reactive T cell population appears as two
to three separate populations (an example is shown as Fig.
3 B), which may reflect slightly distinct affinities for the
primary and secondary antigen.
 
Specificity of Cross-reactive T Cells.
 
Several reports have in-
dicated that the requirements for activating memory T cells
differ from those for activating naive T cells, making them
more susceptible to low-affinity TCR triggering or cyto-
kine-mediated stimulation (35–39). To address the possible
contribution of aspecific or more broadly reactive T cells in
the formation of the cross-reactive T cell population, in-
fluenza A/NT/60/68-primed mice were infected with
the antigenically unrelated influenza B virus (B/Lee/40).
Both at day 4 (data not shown) and day 8 after infection
(Fig. 4, panel 1), no expansion of the influenza A/NT/60/
68-specific memory T cell population is observed. This is
in agreement with results by others showing that by-
stander activation during an acute viral infection is minimal
(20, 40, 41). Furthermore, the influenza A virus–specific
T cells in mice that underwent sequential infections with
A/NT/60/68 and A/PR/8/34 do not bind peptide–
MHC tetramers that contain an adenovirus E1A-derived
CTL epitope (Fig. 4, panel 2). Thus, the cross-reactive T
cell population that expands upon infection of primed mice
does require a significant structural homology between two
antigens that are encountered sequentially, and is specific
for these two peptide–MHC complexes. Finally, selective
outgrowth of cross-reactive T cells does not take place to
an appreciable extent when the two related antigens are in-
troduced simultaneously (Fig. 4, panel 3). This suggests that
the selective advantage of cross-reactive cells relies on
quantitative or qualitative traits of the T memory popula-
tion, such as homing properties or the requirements for co-
stimulatory signals.
 
Structural Requirements for Cross-reactivity.
 
To provide a
first estimate of the extent of structural homology between
two antigens that is required for the selective expansion of
cross-reactive T cells, we searched the National Center for
Biotechnology Information (NCBI) GenBank database for
other natural variants of the H-2D
 
b
 
–restricted influenza NP
epitope. Thus far, 10 variants of this epitope have been
identified, 7 of which contain mutations that affect TCR-
Figure 2. Ex vivo function of
cross-reactive T cells. (A) Cyto-
toxic activity of cross-reactive T
cells. Mice were sequentially in-
fected with A/NT/60/68 (10
HAU) and influenza A/PR/8/34
(200 HAU) and at day 7 after in-
fection, lung-infiltrating CD81
T cells were purified by flow cy-
tometry and directly used as ef-
fector cells in a 5-h 51Cr-release
assay at the indicated E/T ratios.
Top panel: targets were EL-4 cells
(s), EL4 cells incubated with
100 mM of the A/NT/60/68
NP366–374 epitope ASNENM-
DAM (j), or the A/PR/8/34
NP366–374 epitope ASNEN-
METM (m). Bottom panel: pu-
rified CD81 T cells were used as
effector cells in a 5-h 51Cr-
release assay at an E/T ratio of
7:1. Target cells were EL4 cells
preincubated with indicated con-
centrations of either ASNENM-
DAM (j) or ASNENMETM
(m). Titration of the peptide con-
centration to the picomolar range
also results in similar lysis of both
targets. (B) Intracellular IFN-g
staining of spleen cells. Mice were
sequentially infected with A/NT/
60/68 and A/PR/8/34, and on
day 7 after the second infection,
spleen cells were stimulated with
peptides corresponding to the
CTL epitopes of A/NT/60/68
and A/PR/8/34 separately or
combined for 6.5 h. Subse-
quently, cells were stained for sur-
face CD8 and intracellular IFN-g.
Numbers represent the percent-
age of total lymphocytes that are
IFN-g positive. 
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exposed side chains (positions 6, 7, and 8) (reference 22, and
Table I). Because influenza A virus is not a common mouse
pathogen, this set of mutants should be random with respect
to T cell recognition. Synthetic peptides corresponding to
these mutants were generated, and mice that had previously
been exposed to influenza A/NT/60/68 or A/HKx31 were
challenged by subcutaneous immunization. To circumvent
the need of helper T cells for the induction of an effective
CTL response, mice were treated with anti-CD40 mAb
(FGK.45) after vaccination (21, 42–44). These experiments
establish that in most if not all cases where influenza A virus–
primed mice are confronted with antigens that contain a
single mutation within the T cell epitope, an influenza-specific
T cell population emerges that is fully cross-reactive be-
 
tween the primary and secondary antigen (Table I). This
phenomenon is not only observed for conservative substi-
tutions, but also for more drastic amino acid changes (e.g.,
Ala8
 
®
 
Asn). For variants that contain multiple alterations in
TCR-exposed residues, cross-reactivity is observed for some
sequences (e.g., ASNENMDAM
 
®
 
ASNENMETM), but not
for others (e.g., ASNENMDAM
 
®
 
ASNENVEAM). Both
the type of mutation and the contribution of the mutated
residues to the TCR-exposed surface of the peptide are
likely to be determining factors in this regard. For one of
the mutant epitopes (ASNENVETM), the functional be-
havior of the cross-reactive T cells was also tested. In line
with the biochemical data, intracellular IFN-
 
g
 
 staining of
spleen cells that were stimulated with the primary antigen
Figure 3. Cross-reactive cells are oligoclonal T memory cell expansions. (A) Cross-reactive CD81 T
cells display a restricted BV repertoire. Naive (top) or A/NT/60/68-primed mice (bottom) were in-
fected with 10 and 200 HAU of influenza A/PR/8/34, respectively. At 7 d after infection, lung-infil-
trating A/PR/8/34-specific CD81 T cells were analyzed for expression of a series of BV elements by
using a panel of fluorochrome-labeled anti-BV antibodies (PharMingen). Values represent the percent-
age of A/PR/8/34-specific CD81 T cells that stain with a particular anti-BV antibody. (B) Mice were
sequentially infected with influenza virus A/HKx31 and A/NT/60/68. 7 d after the second infection,
mononuclear cells recovered from pulmonary tissue were stained with anti-CD8 and APC-labeled
MHC tetramers with the influenza A/NT/60/68 epitope and PE-labeled MHC tetramers with the in-
fluenza A/PR/8/34 epitope, and analyzed by FACS® analysis. The dot plot reveals three distinct popu-
lations of selectively expanded cross-reactive CD81 T cells. 
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(ASNENMETM) or the peptide variant used for vaccina-
tion revealed an identical percentage of responding cells
(data not shown).
 
In Vivo Function of Cross-reactive T Cells.
 
Cross-protection
or the lack thereof by an epitope-specific T cell population
cannot readily be tested through the use of mutant or re-
combinant viral strains. Even in settings where B cell im-
munity is absent, such as in 
 
m
 
-MT mice, it is difficult to
exclude a possible contribution of T cell responses against
subdominant epitopes that are conserved between the pri-
mary and the recall strain. To circumvent these difficulties,
we developed a model system in which only the T cell
epitope under study is shared between the primary and sec-
ondary antigen encounter. The NP
 
366–374 
 
CTL epitope of
influenza virus strain A/NT/60/68 was introduced into the
EL4 tumor cell line as a COOH-terminal fusion with the
eGFP gene product. Although the parental cell line grows
progressively when injected subcutaneously in C57BL/10
mice, the NP epitope–expressing tumor is rejected over a
2–3-wk time period. Furthermore, tumor rejection is par-
alleled by the appearance of an NP
 
366–374
 
–specific T cell
population and is markedly enhanced by simultaneous in-
fection with influenza virus A/NT/60/68 (Wolkers, M.C.,
manuscript in preparation). Thus, the introduced NP epitope
appears to function as a bona fide (neo)tumor antigen in
this setting, as recognition of this antigen is correlated with
tumor rejection.
To examine the in vivo effects of cross-reactive T cell
populations, mice that had previously been exposed to in-
fluenza virus A/NT/60/68 (carrying the homologous NP
epitope), A/HKx31 (reassortant of A/PR/8/34; carrying a
variant NP epitope), or an unrelated influenza B virus were
challenged with EL4-NP
 
366–374 
 
tumor cells. After tumor cell
injection, blood samples were taken from individual mice
and the frequency of virus strain-specific and cross-reactive
CD8
 
1
 
 T cells was measured. In mice that had been in-
fected with the unrelated influenza B virus (Fig. 5, panel 1),
tumor growth is comparable to that in uninfected mice (data
not shown). As expected, mice that were previously ex-
posed to influenza virus A/NT/60/68, which shares the
CTL epitope with the EL4-NP
 
366–374 
 
tumor, showed a strong
reduction in tumor growth (Fig. 5, panel 1). This protec-
tion is accompanied by a massive and rapid increase in the
number of A/NT/60/68-monospecific T cells, which were
apparently reactivated from the memory T cell pool by the
NP epitope–expressing tumor (Fig. 5, panel 2). Importantly,
intermediate tumor growth was seen in mice that had pre-
viously been infected with variant virus A/HKx31 (Fig. 5,
panel 1). In addition, the reduced tumor outgrowth in these
mice is accompanied by the expansion of a large population
of CD8
 
1
 
 T cells, which cross-react between the NP
 
366–374
 
–
expressing EL4 tumor and the viral strain used for priming
(Fig. 5, panel 3). These results illustrate that the presence of
a structurally related T cell antigen promotes the expansion
of infrequent cross-reactive T cells even in the absence of
any further noticeable homology between primary and sec-
ondary challenge, and this expansion is accompanied by a
significant reduction in tumor outgrowth.
Figure 4. Specificity of cross-
reactive T cells. Panel 1: mice
were sequentially infected with
A/NT/60/68 (10 HAU) and in-
fluenza B/Lee/40 (125 HAU)
and at day 8 after infection, lung-
infiltrating lymphocytes were an-
alyzed for binding of MHC tet-
ramers expressing the A/NT/60/
68-derived epitope, ASNENM-
DAM, and CD8 expression.
Panel 2: mice were sequentially
infected with A/NT/60/68 (10
HAU) and A/PR/8/34 (200
HAU) and at day 7 after infec-
tion, lung-infiltrating CD81 T
cells were analyzed for binding of
APC-labeled MHC tetramers
containing the ASNENMDAM
peptide and PE-labeled MHC
tetramers with the adenovirus
E1A-derived epitope, SGPSNT-
PPEI. Panel 3: mice were in-
fected with A/NT/60/68 (10
HAU) and A/HKx31 (200 HAU)
simultaneously and at day 7 after
infection, lung-infiltrating CD81
T cells were analyzed for the
presence of A/NT/60/68- and
A/PR/8/34-specific T cells. In
all panels, the numbers given rep-
resent the percentage of CD81 T
lymphocytes that stain with the
indicated MHC tetramer(s). 
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Discussion
 
The ability of cytotoxic T cell populations to cross-react
between different viral strains was first appreciated by
Townsend and Skehel in 1984 (18). They showed that re-
peated in vitro restimulation protocols of splenic lympho-
cytes derived from influenza A virus–primed mice could lead
to the selection of NP-specific T cell lines that cross-reacted
between different influenza A viral strains. At that time, it
was unknown whether these T cell lines cross-reacted at the
level of the (variable) immunodominant NP
 
366–374 
 
CTL
epitope, or whether shared subdominant epitopes were
recognized. However, with the benefit of hindsight, these
experiments can be said to have revealed for the first time
the capacity of cytotoxic T cells to productively recognize
viral variants.
In spite of the early recognition of T cell cross-reactivity
in in vitro assays, the biological in vivo significance of this
cross-reactivity for the immune system to cope with viral
variants has since remained unclear. Our findings now doc-
ument that prior antigen exposure dramatically affects the
repertoire of T cells used in a subsequent response to anti-
genic variants in vivo. The propensity for cross-reactivity
between two T cell antigens appears roughly proportional
to the sequence similarity between the epitopes tested, and
seems to be a common event for antigens that are closely
related. These cells that expand in vivo are phenotypically
indistinguishable from conventional effector T cell popula-
tions (CD44
 
high
 
, CD62L
 
low
 
; data not shown) and are func-
tional ex vivo and in vivo. This process appears to be due
to the selective expansion of cross-reactive T cells present
in the memory T cell pool, and is not dependent on shared
B or T helper epitopes between primary and recall antigen.
In recent years, several groups have studied the impact of
epitope variants on antigen-specific T cell responses (for re-
views, see references 6, 45, and 46). These variant epitopes
 
Table I.
 
Sequence Requirements for Cross-reactive T Cells
 
Secondary vaccination Mutation(s)
No. of CD8
 
1
 
 T cells (
 
3
 
1,000)/spleen
Cross-reactive Variant-specific
Primary infection A/NT/60/68 (ASNENMDAM)
ASNENMDTM A
 
®
 
T 1,600 22
ASNENMDTM A
 
®
 
T 650
 
#
 
2
ASNENMDNM A
 
®
 
N 260
 
#
 
5
ASNENMDNM A
 
®
 
N 110
 
#
 
2
ASNENMEAM D
 
®
 
E 160
 
#
 
2
ASNENMEAM D
 
®
 
E1 2
 
#
 
5
ASNENMETM DA
 
®
 
ET 220 12
ASNENMETM DA
 
®
 
ET 41 7
ASNENVEAM MD
 
®VE 20 #1
ASNENVEAM MD®VE #3 #2
ASNENVETM MDA®VET #3 #1
ASNENVETM MDA®VET #2 #5
Primary infection A/HKx31 (ASNENMETM)
ASNENMEAM T®A 100 #4
ASNENMDTM E®D 200 #3
ASNENVETM M®V7 3#4
ASNENMDAM ET®DA 10 6
ASNENMDNM ET®DN #3 #2
ASNENVEAM M.T®V.A 8 #1
Mice were infected with influenza A/NT/60/68 (10 HAU) (top) or A/HKx31 (200 HAU) (bottom). 4–6 wk after the primary infection, mice
were challenged with synthetic peptides corresponding to the various naturally occurring influenza A NP366–374 variants, in combination with anti-
CD40 mAb, FGK.45. At day 10 after challenge, spleen CD81 T cells were analyzed by flow cytometry. Data represent the number of CD81 T cells
per spleen that stain with MHC tetramers of both the primary and secondary NP366–374 epitope or that are specific for the variant antigen. Each data
point represents a single mouse; two mice per peptide challenge with A/NT/60/68, one mouse per peptide challenge with A/HKx31. Variants are
depicted in order of descending homology with the primary antigen, based on the contribution of the mutated residue to the TCR-exposed surface
(reference 22) and the nature of the amino acid substitution. Background values are #0.5 3 104 MHC tetramer–positive CD81 T cells/spleen. For
the NP366–374 epitope, no detectable antigen-specific T cell population can be induced in naive mice by this vaccination strategy, suggesting that this
type of vaccination may not be as effective as a viral infection in inducing a CD81 T cell response (not shown).1326 CD81 Memory T Cell Responses against Viral Variants
were generally isolated as immune escape variants, or were
identified in in vitro assays by their aberrant recognition by
T cell clones. These selected antigen variants function as ei-
ther partial agonists or antagonists of antigen-specific T cell
responses not only in vitro but also in vivo. We sought to
examine whether this type of T cell antagonism or partial
agonism is a common phenomenon when a polyclonal T
cell repertoire is confronted with antigenic variation. To this
purpose, we studied the development of antigen-specific T
cell repertoires after encounter of random natural variants
of influenza A viruses. We conclude that during such en-
counters, the T cell repertoire generally reacts with the out-
growth of a T cell population for which the variant epitope
is a full agonist. The TCRs encoded by these T cells bind
with equal affinity to MHC molecules complexed with
wild-type and variant epitopes. Furthermore, the functional
capacity of this T cell population towards target cells ex-
pressing the original or the variant antigen is indistinguish-
able both in vitro and in vivo.
How do these data fit in with previous observations that
mutations in T cell epitopes can lead to CTL escape by the
virus? During chronic HIV and HBV infections (10, 11), and
also in a murine lymphocytic choriomeningitis virus (LCMV)
model (12), the mechanism that we have identified appar-
ently does not operate efficiently. In theory, this could be due
to the type of amino acid changes in the T cell epitopes in-
volved. However, examination of the type of mutations in
the T cell epitopes in those cases and the mutations studied
here does not point towards obvious differences (not shown).
Alternatively, the impaired ability to react to emerging anti-
genic variants in those settings may be due to alterations at the
T cell level. Specifically, repetitive antigen-specific T cell
stimulation results in a narrowing of the reactive T cell reper-
toire (33). Indeed, the antigen-specific T cell expansions ob-
served during chronic HIV infection are oligoclonal (47). It
may be hypothesized that for such restricted antigen-specific
T cell populations, a single antigenic variant could antagonize
a substantial part of the antigen-specific T cell response, and it
will be a challenge to test this notion in a direct manner.
Why do cross-reactive T cells dominate the response
against antigenic variants over the largely strain-specific re-
sponse observed normally during a primary T cell response?
The cross-reactive T cells that we have identified appear to
originate from the preexisting memory T cell pool, and na-
ive and memory T cells differ both in quantitative and qual-
itative terms. Specifically, even though cross-reactive cells
are infrequent in the original memory pool, these cells may
still outnumber the strain-specific T cells that—due to their
specificity—failed to get activated in the primary response.
In addition, the activation requirements of memory T cells
are less stringent than those of naive T cells (38, 48, 49). This
is reflected in a lessened requirement both for costimulatory
signals and for prolonged antigenic stimulation. Finally, the
ability of memory T cells to enter peripheral tissues may
promote the early encounter of viral antigens (50). Indirect
evidence for functional T cell cross-reactivity during subse-
quent viral infections has been obtained previously. Exper-
iments by Welsh and colleagues (51) have suggested that a
measure of heterologous immunity may occur even for ap-
parently unrelated viruses. Although in that case the anti-
genic determinants involved were not identified and cross-
reactive cells were of low avidity, these results do suggest
that the selective expansion of cross-reactive memory T
cells could be a more general phenomenon.
We conclude that a polyclonal T cell repertoire responds
to the encounter of random variants by the expansion of
memory T cells that are best fit for the recognition of the
variant antigen. These findings suggest that random muta-
tions in T cell epitopes are unlikely to result in CTL escape,
and that a polyclonal T cell memory population can pro-
vide protection not only against the index sequence, but
also against a swarm of related sequences.
Figure 5. In vivo function of
cross-reactive T cells. C57BL/10
mice (six mice per group) were
infected with either A/NT/60/
68 (10 HAU), A/HKx31 (100
HAU), or B/Lee/40 (125 HAU).
3 mo after the infection, all mice
were injected subcutaneously
with 3 3 106 live EL4-NP366–374
tumor cells. 7 d after tumor chal-
lenge, tumor size was measured
and the mean diameter per
mouse is plotted (panel 1). At the
same time point, peripheral
blood samples were taken and
surface stained with anti-CD8
mAb (PharMingen) and differ-
entially labeled MHC tetramers
containing the ASNENMDAM
and ASNENMETM epitopes.
The percentages of A/NT/60/
68-monospecific CD81 T cells
(panel 2) and cross-reactive
CD81 T cells (panel 3) are plot-
ted for individual mice.1327 Haanen et al.
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